{"certainAgreement":{"otherDetails":"Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Aduro ≥ 60 days in advance of submission for publication; (ii) deletes Aduro Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"ADU-CL-16 was terminated early leading to a small number of Phase 1 subjects analyzed."},"pointOfContact":{"email":"clinicaltrials@chinooktx.com","organization":"Chinook Therapeutics, Inc.","phone":"206-485-7051","title":"Chinook Therapeutics, Inc. (formerly Aduro Biotech, Inc.)"}}